GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncotelic Therapeutics Inc (OTCPK:OTLC) » Definitions » Market Cap

Oncotelic Therapeutics (Oncotelic Therapeutics) Market Cap : $15.97 Mil (As of May. 01, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Oncotelic Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Oncotelic Therapeutics's share price for the quarter that ended in Dec. 2023 was $0.03825. Oncotelic Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 399.18 Mil. Therefore, Oncotelic Therapeutics's market cap for the quarter that ended in Dec. 2023 was $15.27 Mil.

Oncotelic Therapeutics's quarterly market cap increased from Jun. 2023 ($9.94 Mil) to Sep. 2023 ($12.34 Mil) and increased from Sep. 2023 ($12.34 Mil) to Dec. 2023 ($15.27 Mil).

Oncotelic Therapeutics's annual market cap declined from Dec. 2021 ($62.97 Mil) to Dec. 2022 ($17.63 Mil) and declined from Dec. 2022 ($17.63 Mil) to Dec. 2023 ($15.27 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Oncotelic Therapeutics's Enterprise Value for Today is $29.19 Mil.


Oncotelic Therapeutics Market Cap Historical Data

The historical data trend for Oncotelic Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncotelic Therapeutics Market Cap Chart

Oncotelic Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.29 19.48 62.97 17.63 15.27

Oncotelic Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.63 18.66 9.94 12.34 15.27

Competitive Comparison of Oncotelic Therapeutics's Market Cap

For the Biotechnology subindustry, Oncotelic Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncotelic Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Oncotelic Therapeutics's Market Cap falls into.



Oncotelic Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Oncotelic Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$0.03825*399.184
=$15.27

Oncotelic Therapeutics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$0.03825*399.184
=$15.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncotelic Therapeutics  (OTCPK:OTLC) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Oncotelic Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Oncotelic Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
29397 Agoura Road, Suite 107, Agoura Hills, CA, USA, 91301
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Executives
Vuong Trieu officer: CHIEF EXECUTIVE OFFICER 4003 JIM BOWIE ROAD, AGOURA HILLS CA 91301
Saran Saund officer: CHIEF BUSINESS OFFICER C/O MATEON THERAPEUTICS INC., 29397 AGOURA RD SUTIE 107, AGOURA HILLS CA 91301
Amit B. Shah officer: CHIEF FINANCIAL OFFICER 10 AGUILA, ALISO VIEJO CA 92656
Chulho Park officer: CHIEF TECHNOLOGY OFFICER 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Steven W King director
David Diamond director 29397 AGOURA RD., SUITE 107, AGOURA HILLS CA 91301
Fatih Uckun 10 percent owner, officer: Chief Medical Officer 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Chao Hsiao 10 percent owner 701 GATEWAY BOULEVARD, SUITE 201, SOUTH SAN FRANCISCO CA 94080
Larn Hwang 10 percent owner C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
Donald Rogers Reynolds director C/O WYRICK ROBBINS YATES & PONTON LLP, 4101 LAKE BOONE TRAIL, SUITE 300, RALEIGH NC 27607
Sandage Bobby W Phd director C/O 99 HAYDEN AVE, 1 LEDGEMONT CENTER, LEXINGTON MA 02173
Simon Pedder director 1001 MAIN STREET, SUITE 600, BUFFALO NY 14203
Matthew M Loar officer: Chief Financial Officer 505 PENOBSCOT DR, REDWOOD CITY CA 94063
Pamela Ha officer: Controller 701 GATEWAY BOULEVARD, SUITE 210, SOUTH SAN FRANCISCO CA 94080